Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
申请人:——
公开号:US20030216325A1
公开(公告)日:2003-11-20
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Substrate specificity profiles are used to determine optimal hepsin substrate sequences, both to the prime side and non-prime side of the hepsin recognition site. The hepsin substrate sequences are used in designing substrates, inhibitors, and prodrugs. For example, prodrugs are provided for use in the treatment of prostate cancer. Hepsin inhibitors based on substrate specificity are also provided.
The invention provides substrate specificity profiles for serine protease prostasin. Optimal prostasin substrate sequences, both to the prime side and non-prime side of the prostasin recognition site, are disclosed herein. The prostasin substrate sequences are used in designing substrates, inhibitors, and prodrugs. Prostasin inhibitors based on substrate specificity are also provided.